In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to recognize Harmless dosing program. Further members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 are going to be supplied as "add-on" therapy. In https://finnstuut.ssnblog.com/31212431/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results